Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Zanubrutinib · 1 trial · 6 indications
CMR rate is defined as the proportion of participants who achieved CMR during study. CMR assessed by PET/CT is defined using Lugano criteria.
CMR rate is defined as the proportion of participants who achieved CMR during study. CMR assessed by PET/CT or CT is defined using Lugano criteria.
| Arm | Type | Description |
|---|---|---|
| Rituxan + Zanubrutinib + Epcoritamab for FL | EXPERIMENTAL | Enrolled participants will complete: * Baseline visit with imaging and bone marrow biopsy * Imaging on cycles 3, 6, 9 * Up to 1 year of treatment with study drugs * End of Treatment visit with imaging and bone marrow biopsy * Follow up visits every 6 months for up to 10 years |
| Rituxan + Zanubrutinib + Epcoritamab for MZL | EXPERIMENTAL | Enrolled participants will complete: * Baseline visit with imaging and bone marrow biopsy * Imaging on cycles 3, 6, 9 * Up to 1 year of treatment with study drugs * End of Treatment visit with imaging and bone marrow biopsy * Follow up visits every 6 months for up to 10 years |
| Name | Type | Description |
|---|---|---|
| Zanubrutinib | DRUG | Bruton tyrosine kinase inhibitor, 80 mg immediate-release capsule, taken orally per protocol. |
| Rituximab | DRUG | Chimeric anti-CD20 monoclonal antibody, 10 or 50 mL single-use vials, via intravenous infusion per institutional standard. |
| Epcoritamab | DRUG | Bispecific antibody, 5 or 60 mg/mL vials, via subcutaneous (under the skin) injection per protocol. |
Inclusion Criteria: * Histologically confirmed diagnosis of CD20+ FL (grade 1-3A) or CD20+ MZL (any subtype) (at time of trial entry) with review of the diagnostic pathology specimen at one of the participating institutions. Patients with current histologic transformation are excluded. * Receipt of...
Zanubrutinib is an investigational small molecule being studied for the treatment of relapsed or refractory Follicular Lymphoma. It is currently in Phase 2 clinical development for this indication, with an ongoing trial evaluating its use in combination with other agents.
Zanubrutinib targets Bruton's tyrosine kinase (BTK) and acts as an inhibitor of this enzyme. By inhibiting BTK, it is designed to interfere with B-cell receptor signaling, which plays a role in the growth and survival of certain lymphoma cells.
Zanubrutinib is being developed by Genmab A/S, a biopharmaceutical company listed on the stock exchange under the ticker symbol GMAB. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with relapsed or refractory Follicular Lymphoma.
Zanubrutinib is currently in Phase 2 clinical development for Follicular Lymphoma. It is an investigational drug, meaning it has not yet been approved by regulatory authorities and is still being studied in clinical trials to assess its safety and effectiveness.
Zanubrutinib is being evaluated in a Phase 2 clinical trial with the identifier NCT06563596. This trial is recruiting patients with relapsed or refractory Follicular Lymphoma, Marginal Zone Lymphoma, and other non-Hodgkin lymphomas. The study is enrolling approximately 45 participants in the United States.
No, Zanubrutinib is not the same as Epco or Ritux. In the clinical trial NCT06563596, Zanubrutinib is being studied in combination with Epco and Ritux for the treatment of relapsed or refractory Follicular Lymphoma and Marginal Zone Lymphoma. Each of these agents has a distinct mechanism of action.